Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run

Taysha's R&D Chief sold $1.2 million in stock following a 149% run. Similarly, UroGen's Chief Medical Officer sold $400,000 in stock after a 191% run. Additionally, a Hinge Health backer sold $38.4 million in stock after a 101% run. These transactions occurred after the respective companies experienced significant stock price increases, leading executives and investors to liquidate portions of their holdings across these three different organizations during the reported periods of growth.